AU2008254669A1 - Use of pimavanserin in the treatment of parkinson and symptoms thereof - Google Patents

Use of pimavanserin in the treatment of parkinson and symptoms thereof Download PDF

Info

Publication number
AU2008254669A1
AU2008254669A1 AU2008254669A AU2008254669A AU2008254669A1 AU 2008254669 A1 AU2008254669 A1 AU 2008254669A1 AU 2008254669 A AU2008254669 A AU 2008254669A AU 2008254669 A AU2008254669 A AU 2008254669A AU 2008254669 A1 AU2008254669 A1 AU 2008254669A1
Authority
AU
Australia
Prior art keywords
pimavanserin
patient
parkinson
disease
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2008254669A
Other languages
English (en)
Inventor
Robert E. Davis
Eve Taylor Mayall
Nathalie Schlienger
Bo-Ragnar Tolf
Daniel P. Van Kammen
Kimberly E. Vanover
David M. Weiner
Hilde Williams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acadia Pharmaceuticals Inc
Original Assignee
Acadia Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acadia Pharmaceuticals Inc filed Critical Acadia Pharmaceuticals Inc
Publication of AU2008254669A1 publication Critical patent/AU2008254669A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2008254669A 2007-05-18 2008-05-19 Use of pimavanserin in the treatment of parkinson and symptoms thereof Abandoned AU2008254669A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US93898507P 2007-05-18 2007-05-18
US60/938,985 2007-05-18
US94299007P 2007-06-08 2007-06-08
US60/942,990 2007-06-08
PCT/US2008/064154 WO2008144665A1 (en) 2007-05-18 2008-05-19 Use of pimavanserin in the treatment of parkinson and symptoms thereof

Publications (1)

Publication Number Publication Date
AU2008254669A1 true AU2008254669A1 (en) 2008-11-27

Family

ID=39739276

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008254669A Abandoned AU2008254669A1 (en) 2007-05-18 2008-05-19 Use of pimavanserin in the treatment of parkinson and symptoms thereof

Country Status (5)

Country Link
EP (1) EP2173343A1 (de)
JP (1) JP2010527938A (de)
AU (1) AU2008254669A1 (de)
CA (1) CA2685606A1 (de)
WO (1) WO2008144665A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090082342A1 (en) * 2007-09-21 2009-03-26 Acadia Pharmaceuticals, Inc. N-substituted piperidine derivatives as serotonin receptor agents
US9446037B2 (en) 2012-11-27 2016-09-20 Acadia Pharmaceuticals Inc. Methods for the treatment of parkinson's disease psychosis using pimavanserin
PT3325444T (pt) 2015-07-20 2021-09-22 Acadia Pharm Inc Métodos para preparar n-(4-fluorobenzil)-n-(1-metilpiperidina-4-il)-n'-(4-(2-metilpropiloxi)fenilmetil)carbamida e o seu sal de tartarato e forma polimórfica c
WO2017165635A1 (en) 2016-03-25 2017-09-28 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome p450 modulators
US10953000B2 (en) 2016-03-25 2021-03-23 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome P450 modulators
WO2018118626A1 (en) 2016-12-20 2018-06-28 Acadia Pharmaceuticals Inc. Pimavanserin alone or in combination for use in the treatment of alzheimer's disease psychosis
EP3615028A1 (de) 2017-04-28 2020-03-04 Acadia Pharmaceuticals Inc. Pimavanserin zur behandlung von impulskontrollstörungen
WO2019046167A1 (en) 2017-08-30 2019-03-07 Acadia Pharmaceuticals Inc. PIMAVANSERIN FORMULATIONS
WO2021030607A1 (en) * 2019-08-15 2021-02-18 Acadia Pharmaceuticals Inc. Pimavanserin for treating neurodegenerative diseases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2289879T3 (pl) * 2004-09-27 2015-05-29 Acadia Pharm Inc Synteza formy krystalicznej soli winianowej n-(4-fluorobenzylo)-n-(1-metylopiperydyn-4-ylo)-n'-(4-(2-metylopropyloksy)fenylometylo)karbamidu
US20070264330A1 (en) * 2006-05-15 2007-11-15 Bo Ragnar-Tolf Pharmaceutical formulations of pimavanserin

Also Published As

Publication number Publication date
WO2008144665A1 (en) 2008-11-27
JP2010527938A (ja) 2010-08-19
CA2685606A1 (en) 2008-11-27
EP2173343A1 (de) 2010-04-14

Similar Documents

Publication Publication Date Title
AU2008254669A1 (en) Use of pimavanserin in the treatment of parkinson and symptoms thereof
Simons H1-receptor antagonists: safety issues
EP2678320B1 (de) Flumazenilkomplexe, zusammensetzungen damit und verwendungen davon
RU2703297C2 (ru) Композиции и способы для лечения бессонницы
CA3079259A1 (en) Ganaxolone for use in treating genetic epileptic disorders
AU2018265353A1 (en) Methods of treating Doose syndrome using fenfluramine
JP2023075247A (ja) ウィルソン病を治療するためのビスコリンテトラチオモリブデート
JP6137833B2 (ja) 脱髄性および他の神経系疾患を患っている患者における神経認知的および／または神経精神医学的障害を改善するための４−アミノピリジンの使用
CA2667924A1 (en) The use of pramipexole or a salt thereof for the treatment of parkinson's disease
US20200330448A1 (en) Compositions and methods for treatment related to fall and fall frequency in neurodegenerative diseases
US20190105315A1 (en) Compositions and methods for treatment related to fall and fall frequency in neurodegenerative diseases
US20190298740A1 (en) Methods and compositions for treating hallucinations and conditions related to the same
AU2018383098A1 (en) Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions
US20200129528A1 (en) Methods for treating blood pressure conditions using aminosterol compositions
US20190307740A1 (en) Compositions and methods for treatment related to fall and fall frequency in neurodegenerative diseases
CN117715641A (zh) 用神经活性类固醇进行治疗的方法
PT2724722T (pt) Método de restaurar o efeito incretina
US20200038415A1 (en) Aminosterol compositions and methods of using the same for treating erectile dysfunction
US20200038417A1 (en) Methods and compositions for treating cognitive impairment
WO2024054412A1 (en) Methods and compositions for treating amyotrophic lateral sclerosis
EP3727043A1 (de) Zusammensetzungen und verfahren zur behandlung im zusammenhang mit fall und fallhäufigkeit bei neurodegenerativen krankheiten
Feret et al. Ebastine: A once-daily nonsedating antihistamine for the treatment of allergic rhinitis
ALLEGRA PATIEMT COUNSELING INFORMATION

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period